Clinical Trial Update: Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sirolimus for segmental overgrowth due to somatic PI3K activation (PROS) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Disorder
• Pik3ca-related Overgrowth Spectrum

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: National Human Genome Research Institute (NHGRI) | Conditions: PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorder | Phase 2 | Status: COMPLETED | Results posted: 2020-01-27